Acorda Therapeutics Cdt Stock
Your prediction
Pros and Cons of Acorda Therapeutics Cdt in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acorda Therapeutics Cdt vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acorda Therapeutics Cdt | - | - | - | - | - | - | - |
| Ardelyx Inc. | 14.210% | 9.666% | 36.225% | 36.030% | 34.894% | 129.432% | 17.691% |
| Evolus Inc | -2.310% | -11.203% | -27.458% | -56.103% | -21.468% | -54.709% | -8.155% |
| Champions Oncology Inc | -1.670% | 7.143% | 2.564% | -34.783% | 3.448% | 50.000% | -35.484% |
Comments
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat
Acorda Therapeutics, Inc. (NASDAQ: ACOR) is now covered by analysts at StockNews.com. They set a "buy" rating on the stock.
Show more
Ratings data for ACOR provided by MarketBeat